Royal Bank Of Canada set a $9.00 price target on Endo International PLC (NASDAQ:ENDP) (TSE:ENL) in a research note issued to investors on Tuesday, October 17th. The firm currently has a hold rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Canaccord Genuity set a $10.00 price objective on shares of Endo International PLC and gave the company a hold rating in a research report on Monday, August 14th. Deutsche Bank AG cut their price objective on shares of Endo International PLC from $18.00 to $15.00 and set a buy rating on the stock in a research report on Friday, July 7th. Cowen and Company reaffirmed a hold rating and issued a $16.00 price objective on shares of Endo International PLC in a research report on Thursday, August 10th. Citigroup Inc. reaffirmed a neutral rating and issued a $11.00 price objective (down from $14.00) on shares of Endo International PLC in a research report on Thursday, August 10th. Finally, BidaskClub cut shares of Endo International PLC from a sell rating to a strong sell rating in a research report on Tuesday, August 8th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $12.64.
Shares of Endo International PLC (ENDP) opened at 5.88 on Tuesday. The firm’s market cap is $1.31 billion. The firm has a 50-day moving average price of $8.43 and a 200-day moving average price of $10.34. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $21.22.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. The company had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Analysts predict that Endo International PLC will post $3.52 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Royal Bank Of Canada Analysts Give Endo International PLC (NASDAQ:ENDP) a $9.00 Price Target” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/endo-international-plc-endp-pt-set-at-9-00-by-royal-bank-of-canada.html.
In other Endo International PLC news, COO Terrance J. Coughlin purchased 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Paul Campanelli purchased 6,500 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was acquired at an average price of $7.71 per share, with a total value of $50,115.00. Following the completion of the transaction, the chief executive officer now owns 213,620 shares in the company, valued at approximately $1,647,010.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 36,000 shares of company stock valued at $279,460. Corporate insiders own 0.50% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of ENDP. Diamond Hill Capital Management Inc. acquired a new stake in shares of Endo International PLC during the second quarter worth $5,454,000. Ameriprise Financial Inc. increased its position in shares of Endo International PLC by 685.0% during the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares during the period. Canada Pension Plan Investment Board increased its position in shares of Endo International PLC by 93.4% during the second quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock worth $6,314,000 after buying an additional 273,024 shares during the period. Sivik Global Healthcare LLC acquired a new stake in shares of Endo International PLC during the second quarter worth $2,793,000. Finally, River & Mercantile Asset Management LLP grew its holdings in Endo International PLC by 116.3% in the third quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock worth $3,071,000 after purchasing an additional 192,790 shares during the period. Institutional investors own 90.13% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.